Citigroup
CRL icon

Citigroup’s Charles River Laboratories CRL Stock Holding History

Citigroup’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,500
Closed -$2.98M – 7750
2019
Q1 		$2.98M Buy
+20,500
New +$2.69M ﹤0.01% 2231

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citigroup's CRL Position: Q1 2026 in Review

Citigroup increased its Charles River Laboratories (CRL) stake by 66% in Q1 2026, buying an estimated $6M and bringing the position to 81,311 shares worth $14M. The position accounts for 0.01% of the portfolio, ranked #1268.

Citigroup first reported a position in CRL in Q2 2013 and has held it in 52 quarters since. The position peaked at $54.9M in Q1 2024. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Citigroup held 81,311 shares of Charles River Laboratories worth $14M as of Q1 2026.
  • Citigroup bought 32,372 Charles River Laboratories shares in Q1 2026, an estimated $6M.
  • Charles River Laboratories made up 0.01% of Citigroup's portfolio in Q1 2026, its #1268 holding.
  • Citigroup first reported a position in Charles River Laboratories in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Charles River Laboratories position peaked at $54.9M in Q1 2024.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.